Science Explorer Back to mapMap
Discussion
Institution · Boehringer Ingelheim (Germany)

Most cited papers from Boehringer Ingelheim (Germany)

Boehringer Ingelheim (Germany)

What are the most cited papers from Boehringer Ingelheim (Germany)?

The most cited paper from Boehringer Ingelheim (Germany) is "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes" (Bernard Zinman, Christoph Wanner, John M. Lachin et al., 2015), with 12,282 citations. Next come "Dabigatran versus Warfarin in Patients with Atrial Fibrillation" (11,272) and "Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke" (6,735).

Showing 50 of 60 papers. Every paper with more than 1,000 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine Open access 17 Sep 2015 12,282
2 Dabigatran versus Warfarin in Patients with Atrial Fibrillation Stuart J. Connolly, Michael D. Ezekowitz, Salim Yusuf et al. · New England Journal of Medicine Open access 30 Aug 2009 11,272
3 Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke Werner Hacke, Markku Kaste, Erich Bluhmki et al. · New England Journal of Medicine Open access 24 Sep 2008 6,735
4 Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure Milton Packer et al. · New England Journal of Medicine Open access 28 Aug 2020 5,214
5 Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis Luca Richeldi et al. · New England Journal of Medicine Open access 18 May 2014 4,731
6 FinnGen provides genetic insights from a well-phenotyped isolated population Mitja Kurki et al. · Nature Open access169 authors 18 Jan 2023 4,362
7 Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes Christoph Wanner, Silvio E. Inzucchi, John M. Lachin et al. · New England Journal of Medicine Open access 14 Jun 2016 3,685
8 Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) Werner Hacke, Markku Kaste, Cesare Fieschi et al. · The Lancet Oct 1998 3,684
9 Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: II. Parameterization and validation Araz Jakalian, D. B. Jack, Christopher I. Bayly · Journal of Computational Chemistry 18 Oct 2002 3,577
10 Membrane transporters in drug development Kathleen M. Giacomini et al. · Nature Reviews Drug Discovery ReviewOpen access Mar 2010 3,373
11 Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Lecia Van Dam Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto et al. · Journal of Clinical Oncology Jul 2013 3,223
12 Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER) Samuel Zachary Goldhaber, Luigi Visani, Marisa De Rosa · The Lancet Apr 1999 2,880
13 Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials Jonathan Emberson et al. · The Lancet ReviewOpen access 5 Aug 2014 2,799
14 Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism Sam Schulman, Clive Kearon, Ajay K. Kakkar et al. · New England Journal of Medicine Open access 6 Dec 2009 2,584
15 Nintedanib in Progressive Fibrosing Interstitial Lung Diseases Kevin R. Flaherty, Athol Umfrey Wells, Vincent Cottin et al. · New England Journal of Medicine Open access 29 Sep 2019 2,440
16 Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials Kennedy R. Lees, Erich Bluhmki, Rüdiger von Kummer et al. · The Lancet May 2010 2,209
17 A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease Donald P. Tashkin, Bartolomé R. Celli, Stephen John Senn et al. · New England Journal of Medicine Open access 5 Oct 2008 2,208
18 Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment Elham Azizi, Ambrose Carr, George Plitas et al. · Cell Open access 28 Jun 2018 2,200
19 A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity Norman Sachs et al. · Cell Open access 7 Dec 2017 2,061
20 Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals Harry M. Olson, Graham R. Betton, Denise E. Robinson et al. · Regulatory Toxicology and Pharmacology Aug 2000 2,056
21 Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Yi-Long Lung Cancer Wu, Caicun Zhou, Chengping Hu et al. · The Lancet Oncology 14 Jan 2014 1,992
22 Molecular requirements for epithelial–mesenchymal transition during tumor progression Margit Anna Huber, Norbert Kraut, Hartmut Beug · Current Opinion in Cell Biology Review 12 Aug 2005 1,830
23 Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma Qiming Zhang et al. · Cell Open access Oct 2019 1,735
24 Structure of a nanobody-stabilized active state of the β2 adrenoceptor Søren G. F. Rasmussen, Hee‐Jung Choi, Juan José Fung et al. · Nature Open access 2011 1,723
25 Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism Guy Meyer et al. · New England Journal of Medicine Open access 9 Apr 2014 1,714
26 Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease Oliver Distler, Kristin B. Highland, Martina Gahlemann et al. · New England Journal of Medicine Open access 20 May 2019 1,667
27 Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia Willemijn J. Jansen et al. · JAMA Open access129 authors 19 May 2015 1,662
28 Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial Laura A. Guay, Philippa Musoke, Thomas R. Fleming et al. · The Lancet Open access Sep 1999 1,654
29 Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials James Chih‐Hsin Yang et al. · The Lancet Oncology 11 Jan 2015 1,596
30 Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial Johannes F.E. Mann, Roland Erich Schmieder, Matthew McQueen et al. · The Lancet Aug 2008 1,593
31 Dabigatran versus Warfarin in Patients with Mechanical Heart Valves John W. Eikelboom, Stuart J. Connolly, Martina Brueckmann et al. · New England Journal of Medicine Sep 2013 1,514
32 Idarucizumab for Dabigatran Reversal Charles V. Pollack, Paul A. Reilly, John W. Eikelboom et al. · New England Journal of Medicine 22 Jun 2015 1,471
33 BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Dan Li, Lauren Ambrogio, Takeshi Shimamura et al. · Oncogene Open access 14 Apr 2008 1,449
34 SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials Faiez M. Zannad, João Pedro Ferreira, Stuart Pocock et al. · The Lancet ReviewOpen access 30 Aug 2020 1,418
35 Sexual Problems and Distress in United States Women Jan Leslie Shifren, Brigitta U. Monz, Patrícia A. Russo et al. · Obstetrics and Gynecology Nov 2008 1,397
36 Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation Christopher Paul Cannon, Deepak L. Bhatt, Jonas Oldgren et al. · New England Journal of Medicine Open access 27 Aug 2017 1,386
37 Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity Joachim Stangier, Sebastian Haertter, Karl‐Heinz Liesenfeld et al. · Thrombosis and Haemostasis 2010 1,381
38 Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus David Z.I. Cherney, Bruce A. Perkins, Nima Soleymanlou et al. · Circulation Open access 13 Dec 2013 1,331
39 Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial Keunchil Park et al. · The Lancet Oncology 12 Apr 2016 1,192
40 Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine Jes Olesen, Hans‐Christoph Diener, Ingo Wilhelm Husstedt et al. · New England Journal of Medicine Open access 10 Mar 2004 1,188
41 Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications Yohei Kawabata, Koichi Wada, Manabu Nakatani et al. · International Journal of Pharmaceutics 31 Aug 2011 1,186
42 PEGylated DNA/transferrin–PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery Manfred Ogris, Silvia Brunner, Susanne Schüller et al. · Gene Therapy Apr 1999 1,179
43 Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis Luca Richeldi, Ulrich Costabel, Moisés Selman et al. · New England Journal of Medicine Open access 21 Sep 2011 1,178
44 The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore–microtubule attachment and in maintaining the spindle assembly checkpoint Silke Hauf, Richard W. Cole, Sabrina LaTerra et al. · The Journal of Cell Biology Open access 21 Apr 2003 1,174
45 Idarucizumab for Dabigatran Reversal — Full Cohort Analysis Charles V. Pollack et al. · New England Journal of Medicine Open access 11 Jul 2017 1,155
46 Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients Ele Ferrannini, Elza Muscelli, Silvia Frascerra et al. · Journal of Clinical Investigation Open access 26 Jan 2014 1,145
47 Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial Bengt I. Eriksson, Ola Einar Dahl, Nadia Rosencher et al. · The Lancet Sep 2007 1,120
48 The reporting odds ratio and its advantages over the proportional reporting ratio Kenneth Jay Rothman, Stephan Lanes, Susan T. Sacks · Pharmacoepidemiology and Drug Safety Aug 2004 1,118
49 Cooperative interactions of LFA-1 and Mac-1 with intercellular adhesion molecule-1 in facilitating adherence and transendothelial migration of human neutrophils in vitro. C. Wayne Smith, Sandrine Marlin, Robert Rothlein et al. · Journal of Clinical Investigation Open access Jun 1989 1,109
50 Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen et al. · JAMA Open access 12 Nov 2018 1,099

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.